

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
ACTING AS THE DESIGNATED/ELECTED OFFICE

In Re Patent Application Of: Jeffrey D. Rothstein, *et al.*

Application No.: 10/576,670
(International Application No. PCT/US2004/035011)

Filed: --
(International Filing Date: 21 October 2004)

Customer No.: 23973


Title: NEUROPROTECTION WITH BETA-LACTAM
COMPOUNDS

INFORMATION DISCLOSURE STATEMENT

MAIL STOP PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, submitted herewith are copies of the references listed in the accompanying Form PTO-1449, except for any US patents and published US patent applications which may be listed.

<p align="center">CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.10</p> <p>EXPRESS MAIL Mailing Label Number: <u>EV5471175945</u> Date of Deposit: <u>2/2/07</u></p> <p>I hereby certify that this correspondence, along with any paper referred to as being attached or enclosed, and/or fee, is being deposited with the United States Postal Service, "EXPRESS MAIL-POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10, on the date indicated above, and addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.</p> <p align="right"> _____ Signature of person mailing page: <u>Jennifer R. Hanna</u> _____ Type or print name of person</p>
--

The Examiner is respectfully requested to review the items listed on the attached form and make them of record in the instant application as required by M.P.E.P. §609. It is requested that the Examiner initial the enclosed duplicate Form 1449, and return one copy to the undersigned.

This Statement should not be construed as a representation that the cited references are material.

This Statement is being submitted before receipt of any office action on the merits. Thus, no fee is due for the filing of this paper. However, if a fee is due, please charge deposit account 50-0573.

Respectfully submitted,

JEFFREY D. ROTHSTEIN, *et al.*

BY 

DANIEL A. MONACO
Registration No. 30,480
DRINKER BIDDLE & REATH LLP
One Logan Square
18th and Cherry Streets
Philadelphia, PA 19103-6996
TEL: (215) 988-3312
FAX: (215) 988-2757
Attorney for Applicants

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 46594-0004-01-US	Serial Number: 10/576,670
	APPLICANT: Jeffrey D. Rothstein	
	Filing Date: Not Yet Assigned	GROUP Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	AA	US 5,462,965	10/31/1995	Roba et al.	514	443	
	AB	US 5,658,782	08/19/1997	Amara et al.	435	365	
	AC	US 5,795,563	08/18/1998	Kallick	424	9.361	
	AD	US 6,248,360	06/19/2001	Choi et al.	424	487	
	AE	US 6,426,342	07/30/2002	Koppel	514	210.06	
	AF	US 6,489,319	12/03/2002	Koppel et al.	514	210.08	
	AG	US 6,610,681	08/26/2003	Koppel	514	210.06	
	AH	US 6,627,625	09/30/2003	Koppel	514	198	
	AI	US 6,833,478	12/21/2004	Bottaro et al.	564	107	
	AJ	US 2002/0002159	01/03/2002	Koppel	514	210.09	
	AK	US 2002/0013270	01/31/2002	Bolte	514	8	
	AL	US 2002/0028761	03/07/2002	Koppel et al.	514	1	
	AM	US 2002/0183304	12/05/2002	Koppel	514	210.1	
	AN	US 2003/0060617	03/27/2003	Lin et al.	536	23.6	
	AO	US 2003/0158172	08/21/2003	Koppel et al.	514	192	
	AP	US 2003/0203881	10/30/2003	Duncan	514	152	
	AQ	US 2004/0014739	01/22/2004	Koppel	514	210.09	
	AR	US 2004/0191803	09/30/2004	Gallagher et al.	435	6	
	AS	US 2005/0048488	03/03/2005	Rothstein	435	6	
	AT	US 2006/0121488	6/8/2006	Rothstein	435	6	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION <u>YES</u> <u>NO</u>	
	AU	WO 03/097024	11/27/2003	PCT	A61K	31/00		
	AV	WO 04/076675	9/10/2004	PCT	C12P			

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	AW	Alaoui et al., "Accute effects of irradiation on the rat brain: protection by glutamate blockade", <i>Eur. J. Pharm.</i> , 276: 55-60 (1995).
	AX	Arriza et al., "Functional Comparisons of Three Glutamate Transporter Subtypes Clones from Human Motor Cortex", <i>J. Neurosci.</i> , 14(9): 5559-69 (1994).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 46594-0004-01-US	Serial Number: 10/576,670
	APPLICANT: Jeffrey D. Rothstein	
	Filing Date: Not Yet Assigned	GROUP Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AY	Bristol et al., "Glutamate Transporter Gene Expression in Amyotrophic Lateral Sclerosis Motor Cortex", <i>Ann. Neurol.</i> , 39: 676-79 (1996).
AZ	Brown et al., "Amyotrophic Lateral Sclerosis – A New Role for Old Drugs", <i>New Engl. J. Med.</i> , 352(13): 1376-78 (2005).
BA	Danbolt, "Glutamate uptake", <i>Prog. Neurobiol.</i> , 65(1): 1-105 (2001).
BB	Fray et al., "The expression of the glial glutamate transporter protein EAAT2 in motor neuron disease: an immunohistochemical study", <i>Eur. J. Neurosci.</i> , 10(8): 2481-89 (1998).
BC	Gegelashvili et al., "Glutamate receptor agonists up-regulate glutamate transporter GLAST in astrocytes", <i>NeuroReport</i> , 8(1): 261-65 (1996).
BD	Gegelashvili et al., "High Affinity Glutamate Transporters: Regulation of Expression and Activity", <i>Mol. Pharm.</i> , 52: 6-15 (1997).
BE	Gegelashvili et al., "Neuronal soluble factors differentially regulate the expression of the GLT1 and GLAST glutamate transporters in cultured astroglia", <i>J. Neurochem.</i> , 69(6): 2612-15 (1997).
BF	Gegelashvili et al., "The high-affinity glutamate transporters GLT1, GLAST, and EAAT4 are regulated via different signaling mechanisms", <i>Neurochem. Int.</i> , 37(2-3): 163-70 (2000).
BG	Gegelashvili et al., "Regulation of glutamate transporters in health and disease", <i>Prog. Brain Res.</i> , 132: 267-86 (2001).
BH	Howland et al., "Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS)", <i>PNAS</i> , 99(3): 1604-1609 (2002).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 46594-0004-01-US	Serial Number: 10/576,670
	APPLICANT: Jeffrey D. Rothstein	
	Filing Date: Not Yet Assigned	GROUP Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

BI	Italian ALS Study Group, <i>Eur. J. Neurol.</i> 3, 295-98 (1996).
BJ	Li et al., "Glutamate Transporter Alterations in Alzheimer Disease Are Possibly Associated with Abnormal APP Expression", <i>J. Neuropath. Exp. Neurol.</i> , 56(8): 901-911 (1997).
BK	Lin et al., "Aberrant RNA Processing in a Neurodegenerative Disease: the Cause for Absent EAAT2, a Glutamate Transporter, in Amyotrophic Lateral Sclerosis", <i>Neuron.</i> , 20(3): 589-602 (1998).
BL	Meyer et al., "Alternative splicing of the glutamate transporter EAAT2 (GLT-1)", <i>Neurosci. Lett.</i> , 241: 68-70 (1998).
BM	Miller et al., "Clinical trials of riluzole in patients with ALS. ALS/Riluzole Study Group-II", <i>Neurology</i> , 47 (Suppl. 2): S86-90; discussion S90-92 (1996).
BN	Rothstein et al., "Decreased Glutamate Transport by the Brain and Spinal Cord in Amyotrophic Lateral Sclerosis", <i>New Eng. J. Med.</i> , 326: 1464-68 (1992).
BO	Rothstein et al., "Selective Loss of Glial Glutamate Transporter GLT-1 in Amyotrophic Lateral Sclerosis", <i>Ann. Neurol.</i> , 38: 73-84 (1995).
BP	Rothstein et al., "Knockout of Glutamate Transporters Reveals a Major Role for Astroglial Transport in Excitotoxicity and Clearance of Glutamate", <i>Neuron</i> , 16: 675-86 (1996).
BQ	Rothstein et al., "Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 90, pp. 6591-6595 (July 1993)
BR	Rothstein, "Therapeutic horizons for amyotrophic lateral sclerosis", <i>Curr. Opin. Neurobiol.</i> , 6(5): 679-87 (1996).
BS	Rowland, et al., "Amyotrophic Lateral Sclerosis", <i>N. Engl J Med</i> , Vol. 344, No. 22, May 31, 2001
BT	Su et al., "Insights into glutamate transport regulation in human astrocytes: Cloning of the promoter for excitatory amino acid transporter 2 (EAAT2)", <i>Proc. Nat. Acad. Sci., USA</i> , 100(4): 1955-60 (2003).
BU	Tikka et al., "Tetracycline derivatives and ceftriaxone, a cephalosporin antibiotic, protect neurons against apoptosis induced by ionizing radiation", <i>J. Neurochem.</i> , 78: 1409-1414 (2001).
BV	Zelenai et al., "Epidermal Growth Factor Receptor Agonists Increase Expression of Glutamate Transporter GLT-1 in Astrocytes through Pathways Dependent on Phosphatidylinositol 3-Kinase and Transcription Factor NF- κ B", <i>Mol. Pharmacol.</i> , 57: 667-678 (2000).

EXAMINER**DATE CONSIDERED**

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.